TLR2∆22 (-196-174) significantly increases the risk of breast cancer in females carrying proline allele at codon 72 of TP53 gene: a case–control study from four ethnic groups of North Eastern region of India

Abstract

Breast cancer (BC) is the second most common cancer in women. In the North Eastern Region (NER) of India, BC is emerging as an important concern as evidenced by the data available from population and hospital-based cancer registries. Studies on genetic susceptibility to BC are important to understand the increase in the incidence of BC in NER. The present case control study was conducted to investigate the association between tumour suppressor gene TP53 codon 72 polymorphism and innate immune pathway gene TLR2∆22 (-196-174) polymorphism with BC in females of NER of India for the identification of novel biomarker of BC. Four hundred sixty-two histopathologically confirmed BC cases from four states of NER of India, and 770 healthy controls were included by organizing community surveys from the neighbourhood of cases. In our study, no significant association between TP53 codon 72 polymorphisms and the risk of BC was found. However, our study has shown that TP53 codon 72 polymorphism is an important effect modifier. In the present study it was found that females carrying 22 base-pair deletion in the promoter region of their TLR2 gene had two times (AOR= 2.18, 95 % CI 1.13-4.21, p=0.019 in dominant model; AOR= 2.17, 95 % CI 1.09-4.34, p=0.027 in co-dominant model) increased risk of BC whwn they also carry proline allele at codon 72 of their TP53 gene.

Association of VDR gene polymorphisms and 22 bp deletions in the promoter region of TLR2Δ22 (‐196‐174) with increased risk of pulmonary tuberculosis: A case‐control study in tea garden communities of Assam

“…Studies have shown that 22 bp deletion at the promoter region of TLR2Δ22 gene is significantly associated with an increased risk of prostate cancer, gastric cancer, bladder cancer, cervical cancer, and chronic hepatitis C . We have also found that 22 bp deletion at the promoter region of TLR2Δ22 (‐196‐174) gene is significantly associated with an increased risk of stomach cancer and breast cancer in NE region of India . Moreover, molecular epidemiological studies have also shown that TLR2Δ22 (‐196‐174) significantly associated with an increased the risk of PTB .…”

“…Conditions for restriction enzyme digestion and data interpretation have been presented in Table . Genotyping of TLR2Δ22(‐196‐174) was performed using allele‐specific primer pairs as described earlier . The amplified PCR products of TLR2Δ22 (‐196‐174) were run on 10% polyacrylamide gel electrophoresis (PAGE), and gel images was captured in a gel documentation system.…”

-196 to -174del, rs4696480, rs3804099 polymorphisms of Toll-like receptor 2 gene impact the susceptibility of cancers: evidence from 37053 subjects

“…The results of pooled analysis for TLR2 polymorphism and cancer susceptibility are provided in Table 2 . For -196 to -174del, we collected 18 articles containing 3943 cases and 4574 controls [1][2][3]6,[8][9][10][11][12][28][29][30][31][32][33][34][35][36]. In the overall analysis, -196 to -174del significantly increased the risk of cancer [B vs. A (OR = 1.468, 95% Cl = 1.129-1.91, P=0.005); BB vs. AA (OR = 1.716, 95% Cl = 1.178-2.5, P=0.005); BA vs. AA (OR = 1.408, 95% Cl = 1.092-1.816, P=0.008); BB+BA vs. AA (OR = 1.449, 95% Cl = 1.107-1.897, P=0.007); BB vs. BA+AA (OR = 1.517, 95% Cl = 1.092-2.107, P=0.013)] ( Figure 2).…”

“…Articles included in our research must meet the following conditions: (1) study the relationship between cancer risk and TLR2 polymorphism; (2) provide sufficient data for extraction and calculation; (3) subjects are human patients; (4) the case-control study included control group and cancer patients case group. When duplicate data appeared in different publications, only the latest publication data were used.…”

“…As we all know, genes are inextricably linked to the development of cancer. In many cancer studies, such as gastric cancer [1], colorectal cancer, breast cancer [2], cervical cancer [3], Toll-like receptor (TLR)-2 (TLR2) has been determined as a pathogenic factor involved in tumorigenesis. The TLR2 gene located on human chromosome 4q32, includes one coding exon and two non-coding exons [4].…”